SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Data From Follow-Up Study of Vertex Pharmaceuticals Incorporated' KALYDECO™ (ivacaftor) Showed Durable Improvements in Lung Function and Other Measures of Disease in People With Cystic Fibrosis Who Have a Specific Genetic Mutation (G551D)
Your Message